Nonsteroidal therapy of sarcoidosis

Current Opinion in Pulmonary Medicine

Volumn 19, Issue 5, 2013, Pages 516-523

  Korsten, Peter ^a   Mirsaeidi, Mehdi ^b   Sweiss, Nadera J ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

corticosteroids; Disease modifying antisarcoid drugs; Sarcoidosis; TNF inhibitor

Indexed keywords

ADALIMUMAB; ANTIMALARIAL AGENT; ANTIMETABOLITE; ANTIOXIDANT; APREMILAST; ARMODAFINIL; AZATHIOPRINE; CHLOROQUINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; METHYLPHENIDATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOXIFYLLINE; QUERCETIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR;

BIOLOGICAL THERAPY; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG INDICATION; DRUG RESEARCH; DRUG TOLERABILITY; HUMAN; REVIEW; SARCOIDOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; BIOLOGICAL PRODUCTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; MYCOPHENOLIC ACID; SARCOIDOSIS, PULMONARY; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881670568     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3283642ad0     Document Type: Review

References (39)

1. Barba K, Gobunsuy R, Judson MA, Beegle SH. Current and emerging pharmacological treatments for sarcoidosis: A review. Drug Des Devel Ther 2013; 7:325-338
2. Baughman RP, Nunes H, Sweiss NJ, Lower EE. Established and experimental medical therapy of pulmonary sarcoidosis. Eur Respir J 2013; 41:1424-1438
3. Judson MA. The treatment of pulmonary sarcoidosis. Respir Med 2012; 106:1351-1361
4. Baughman RP, Meyer KC, Nathanson I, et al. Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 142:e1S-e111S.
5. Vorselaars AD, Wuyts WA, Vorselaars VM, et al. Methotrexate versus azathioprine in second line therapy of sarcoidosis. Chest 2013. [Epub ahead of print]
6. Liu LL, Jiang Y, Wang LN, et al. Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis; a meta-analysis of randomized controlled trials. Drugs 2012; 72:1521-1533
7. Brill AK, Ott SR, Geiser T. Effect and safety of mycophenolate mofetil in chronic pulmonary sarcoidosis: A retrospective study. Respiration 2012. [Epub ahead of print]
8. Lee SW, Park HJ, Kim BK, et al. Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate. Arthritis Res Ther 2012; 14:R232
9. Lahmer T, Knopf A, Lanzl L, et al. Using TNF-alpha antagonist adalimumab for treatment for multisystem sarcoidosis: A case study. Rheumatol Int 2012; 32:2367-2370
10. Milman N, Graudal N, Loft A, et al. Effect of the TNF-alpha inhibitor adalimumab in patients with recalcitrant sarcoidosis: A prospective observational study using FDG-PET. Clin Respir J 2012; 6:238-247
11. Russell E, Luk F, Manocha S, et al. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy. Semin Arthritis Rheum 2013. [Epub ahead of print]
12. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174:795-802
13. Erckens RJ, Mostard RL, Wijnen PL, et al. Adalimumab successful in sarcoidosis patients with refractory chronic noninfectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012; 250:713-720
14. Elfferich MD, Nelemans PJ, Ponds RW, et al. Everyday cognitive failure in sarcoidosis: The prevalence and the effect of anti-TNF-alpha treatment. Respiration 2010; 80:212-219
15. Vigne C, Tebib JG, Pacheco Y, et al. Sarcoidosis: An underestimated and potentially severe side effect of anti-TNF-alpha therapy. Joint Bone Spine 2013; 80:104-107
16. Bhamra K, Stevens R. Pulmonary sarcoidosis following etanercept treatment. Case Rep Rheumatol 2012; 2012:724013
17. Redelman-Sidi G, Sepkowitz KA. Interferon gamma release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med 2013. [Epub ahead of print]
18. Malviya G, Salemi S, Lagana B, et al. Biological therapies for rheumatoid arthritis: Progress to date. BioDrugs 2013. [Epub ahead of print]
19. Beccastrini E, Vannozzli L, Bacherini D, et al. Successful treatment of ocular sarcoidosis with rituximab. Ocul Immunol Inflamm 2013; 21:244-246
20. Julian MW, Shao G, Schlesinger LS, et al. Nicotine treatment improves Tolllike receptor 2 and Toll-like receptor 9 responsiveness in active pulmonary sarcoidosis. Chest 2013; 143:461-470
21. Zimmermann A, Dubaniewicz A, Slominski JM. Pharmacotherapy for sarcoidosis: An example of an off-label procedure. Adv Exp Med Biol 2013; 755:251-256
22. DeFelice T, Fischer M, Kamino H, et al. Verrucous and macular sarcoidosis. Dermatol Online J 2012; 18:10
23. Bouaziz A, Le Scanf J, Chapelon-Abric C, et al. Oral involvement in sarcoidosis: Report of 12 cases. QJM 2012; 105:755-767
24. Sakellariou GT, Anastasilakis AD, Karanikolas D, et al. Central skeletal sarcoidosis: A case report with sustained remission only on methotrexate, and a literature review on the imaging approach, treatment, and assessment of disease activity. Mod Rheumatol 2013; 23:175-181
25. Vasaghi A, Kalafi A. Unusual manifestation of cutaneous sarcoidosis; a case report of morpheaform sarcoidosis. Acta Med Iran 2012; 50:648-651
26. Meyersburg D, Schon MP, Bertsch HP, Seitz CS. Uncommon cutaneous ulcerative and systemic sarcoidosis. Successful treatment with hydroxychloroquine and compression therapy. Hautarzt 2011; 62:691-695
27. Sahoo DH, Bandyopadhyay D, Xu M, et al. Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis. Eur Respir J 2011; 38:1145-1150
28. Androdias G, Maillet D, Marignier R, et al. Mycophenolate mofetil may be effective in CNS sarcoidosis but not in sarcoid myopathy. Neurology 2011; 76:1168-1172
29. Zhao L, Jiang Z, Jiang Y, et al. Changes in immune cell frequencies after cyclophosphamide or mycophenolate mofetil treatments in patients with systemic lupus erythematosus. Clin Rheumatol 2012; 31:951-959
30. Poormoghim H, Moradi Lakeh M, Mohammadipour M, et al. Cyclophosphamide for scleroderma lung disease: A systematic review and meta-analysis. Rheumatol Int 2012; 32:2431-2444
31. Baughman RP, Judson MA, Ingledue R, et al. Efficacy and safety of apremilast in chronic cutaneous sarcoidosis. Arch Dermatol 2012; 148:262-264
32. Knopf A, Lahmer T, Chaker A, et al. Head and neck sarcoidosis, from wait and see to tumor necrosis factor alpha therapy: A pilot study. Head Neck 2013; 35:715-719
33. Bejerano C, Blanco R, Gonzá lez-Vela C, et al. Refractory polymyalgia rheumatica as presenting manifestation of large-vessel vasculitis associated to sarcoidosis. Successful response to adalimumab. Clin Exp Rheumatol 2012; 30 (1 Suppl. 70):S94-S97
34. O'Reilly MW, Sexton DJ, Dennedy MC, et al. Radiological remission and recovery of thirst appreciation after infliximab therapy in adipsic diabetes insipidus secondary to neurosarcoidosis. QJM 2013. [Epub ahead of print]
35. Boots AW, Drent M, De Boer VC, et al. Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin Nutr 2011; 30:506-512
36. Hoitsma E, Faber CG, van Santen-Hoeufft M, et al. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23:73-77
37. Heij L, Dahan A, Hoitsma E. Sarcoidosis and pain caused by small-fiber neuropathy. Pain Res Treat 2012; 2012:256024
38. Heij L, Neisters M, Swartjes M, et al. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: A randomized, double-blind pilot study. Mol Med 2012; 18:1430-1436
39. Drent M, Lower EE, De Vries J. Sarcoidosis-associated fatigue. Eur Respir J 2012; 40:255-263